Cite
HARVARD Citation
Diefenbach, C. et al. (2021). Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet. 8 (12), pp. e891-e901. [Online].